Olpha

JSC Olpha (formerly JSC Olainfarm) is a Latvian leading manufacturer in the chemical and pharmaceutical sector of the Baltic States.

The company was founded in 1972 as state enterprise "Olaines ķīmiski – farmaceitiskā rūpnīca" (Olaine Chemical-Pharmaceutical Plant). The main goal of founding the company was to supply pharmaceutical substances and intermediates to several finished drug form manufacturing plants in the Soviet Union. As a result of privatization in 1997, the company was reorganized into a joint stock company, and its shares were publicly listed. Since its initial public offering, Olainfarm has grown into a global company with representative offices in Ukraine, Tajikistan, Albania, Armenia, Kazakhstan, Kosovo, Uzbekistan and Mongolia. Olainfarm furthermore operates subsidiary companies in Latvia, Lithuania, Turkey, Azerbaijan and Kyrgyzstan, and works with contracted agents in the USA, Serbia, Turkmenistan, Moldova, Sweden and Southeast Asia.

Olainfarm produces over 60 final dosage forms, 25 active pharmaceutical ingredients and 20 intermediates. Their key areas of specialization in final dosage forms include neurology (cholinesterase inhibitors, anxiolytics, psychostimulants, nootropics), cardiology (antiarrhythmics, energy metabolism enhancers), infectology (original nitrofurantoine derivatives and antivirals) and allergology (fast acting antihistamines).

Olainfarm is certified in accordance with the requirements of the EU GMP for APIs and FDFs, the U.S. cGMP for certain APIs (FDA), TGA for FDFs (Australia), CEP for certain APIs, ISO 14001 Environmental Management System and ISO 17025 Laboratory Management System.

Olainfarm has cooperated with companies and organizations around the world, including Novartis, Dr. Reddy's, Glenmark Generics, Sigma AU, Almirall Ranke, UQUIFA, MIAT, Actavis, Teva, Egis, and PHF among others.